Cipla Limited — Artemether Exporter Profile
Indian Pharmaceutical Exporter · #15 for Artemether · $3.9M export value · DGFT Verified
Cipla Limited is the #15 Indian exporter of Artemether with $3.9M in export value and 181 verified shipments. Cipla Limited holds a 0.9% market share in Artemether exports across 15 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Artemether Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Artemether?
| Country | Value | Shipments | Share |
|---|---|---|---|
| MOZAMBIQUE | $731.4K | 27 | 18.9% |
| TOGO | $721.3K | 22 | 18.6% |
| DENMARK | $493.2K | 21 | 12.7% |
| PAKISTAN | $374.7K | 33 | 9.7% |
| KENYA | $320.8K | 8 | 8.3% |
| GHANA | $309.3K | 9 | 8.0% |
| BURUNDI | $201.7K | 7 | 5.2% |
| CHAD | $187.6K | 7 | 4.8% |
| FRANCE | $164.5K | 9 | 4.2% |
| TANZANIA | $156.2K | 11 | 4.0% |
Cipla Limited exports Artemether to 15 countries. The largest destination is MOZAMBIQUE accounting for 18.9% of Cipla Limited's Artemether shipments, followed by TOGO (18.6%) and DENMARK (12.7%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Artemether from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CMAM | MOZAMBIQUE | $731.4K | 27 |
| PRIMATURE UNITE DE GESTION DES PROJ | TOGO | $721.3K | 22 |
| UNICEF COPENHAGEN | DENMARK | $403.8K | 16 |
| DIRECTORATE OF MALARIA CONTROL | PAKISTAN | $374.7K | 33 |
| NATIONAL MEDICAL STORES | KENYA | $320.8K | 8 |
| GHANA MINISTRY OF HEALTH | GHANA | $309.3K | 9 |
| UNDP COUNTRY OFFICE BURUNDI | BURUNDI | $201.7K | 7 |
| UNITE DE GESTION DES PROJETS (UGP) | CHAD | $187.6K | 7 |
| UNICEF BANGUI | CENTRAL AFRICA | $94.3K | 5 |
| UNICEF SUPPLY DIVISION | DENMARK | $79.1K | 4 |
Cipla Limited supplies Artemether to 21 buyers globally. The largest buyer is CMAM (MOZAMBIQUE), followed by PRIMATURE UNITE DE GESTION DES PROJ (TOGO) and UNICEF COPENHAGEN (DENMARK). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Artemether Export Value and How Much Does Cipla Limited Contribute?
India exported $155.1M worth of Artemether through 8,652 shipments from 481 suppliers to 107 countries, serving 1,561 buyers globally. Cipla Limited contributes $3.9M to this total, accounting for 0.9% of India's Artemether exports. Cipla Limited ships Artemether to 15 countries through 21 buyers.
What Is the Average Shipment Value for Cipla Limited's Artemether Exports?
Cipla Limited's average Artemether shipment value is $21.4K per consignment, based on 181 shipments totaling $3.9M. The largest destination is MOZAMBIQUE (18.9% of Cipla Limited's Artemether exports).
How Does Cipla Limited Compare to Other Indian Artemether Exporters?
Cipla Limited ranks #15 among 481 Indian Artemether exporters with a 0.9% market share. The top 3 exporters are IPCA LABORATORIES LIMITED ($30.0M), MACLEODS PHARMACEUTICALS LTD ($25.5M), INNOVA CAPTAB LIMITED ($16.2M). Cipla Limited processed 181 shipments to 15 destination countries.
What Artemether Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| LUMARTEM DT (ARTEMETHER & LUMEFANTRINE D | $1.0M | 40 |
| LUMARTEM DT TABLETS (ARTEMETHER & LUMEFA | $731.4K | 27 |
| LUMARTEM DT ARTEMETHER & LUMEFANTRINE DISPERSIBLE TABLETS 20 / 120 MG | $275.5K | 7 |
| LUMARTEM DT ARTEMETHER & LUMEFANTRINE D | $110.4K | 4 |
| LUMARTEM DT (ARTEMETHER & LUMEFANTRINE DISPERSIBLE TABLETS 20 / 120 MG) (3195 PACK,PACK SIZE 30 X 12'S) | $102.3K | 3 |
| LUMARTEM DT (ARTEMETHER & LUMEFANTRINE DISPERSIBLE TABLETS 20 / 120 MG)(3240 PACK,PACK SIZE 30X12'S)NOS | $74.7K | 6 |
| LUMARTEM TABLET (ARTEMETHER 20MG+LUMEFAN | $73.7K | 5 |
| LUMARTEM DT (ARTEMETHER & LUMEFANTRINE DISPERSIBLE TABLETS 20 / 120 MG)(3195 PACK,PACK SIZE 30X12'S)NOS | $73.7K | 6 |
| LUMARTEM (ARTEMETHER 20 MG + LUMEFANTRIN | $53.3K | 4 |
| LUMARTEM DT ARTEMETHER & LUMEFANTRINE DISPERSIBLE TABLETS 20 / 120 MG Remitter :Stichting Iplussolutions Netherlands | $45.3K | 1 |
Cipla Limited exports 66 distinct Artemether formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LUMARTEM DT (ARTEMETHER & LUMEFANTRINE D with 40 shipments worth $1.0M.
How Does Cipla Limited Compare to Nearest Artemether Exporters?
Exporters ranked immediately above and below #15 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 13 | LINCOLN PHARMACEUTICALS LTD | $4.3M | 86 | 7 | $50.0K |
| 14 | BIOMATRIX HEALTHCARE PRIVATE LIMITED | $4.0M | 81 | 5 | $50.0K |
| 15 | CIPLA LIMITED ★ | $3.9M | 181 | 15 | $21.4K |
| 11 | SANJEEVANI BIO-TECH EXIM PRIVATE LIMITED | $2.5M | 51 | 2 | $50.0K |
Cipla Limited ranks #15 among 481 Indian Artemether exporters. Average shipment value of $21.4K compared to the market average of $322.4K. The closest competitors by value are LINCOLN PHARMACEUTICALS LTD and BIOMATRIX HEALTHCARE PRIVATE LIMITED.
Which Indian Ports Ship Artemether Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,326 | 15.3% |
| JNPT/ NHAVA SHEVA SEA | 817 | 9.4% |
| JNPT | 788 | 9.1% |
| SAHAR AIR | 757 | 8.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 622 | 7.2% |
| AHEMDABAD ICD | 420 | 4.9% |
| NHAVA SHEVA SEA | 272 | 3.1% |
| MUNDRA SEA | 269 | 3.1% |
Geopolitical & Trade Policy Impact on Cipla Limited's Artemether Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Artemether, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Artemether — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Artemether shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 181 individual customs records matching Cipla Limited exporting Artemether, covering 66 formulations to 15 countries via 21 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 107+ countries, 1,561+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Artemether Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Artemether exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Artemether Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Artemether. For current shipment-level data, contact TransData Nexus.